KDM1A and brain neoplasm: Importantly, the development of LSD1 inhibitor-based combination treatment strategies for brain tumors needs to prioritize brain penetrance and limited toxicity to non-transformed neuronal cells with enhanced efficacy as an adjunct treatment.